Omtriptolide - Pharmagenesis/Pierre Fabre
Alternative Names: F 60008; PG 49088; PG490-88Na; TriptoSarLatest Information Update: 28 Jul 2021
At a glance
- Originator Pharmagenesis
- Developer Pharmagenesis; Pierre Fabre
- Class Antineoplastics; Phenanthrenes; Small molecules
- Mechanism of Action Apoptosis stimulants; Calcium channel modulators; Immunosuppressants; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Myeloid leukaemia; Solid tumours
- Discontinued Graft-versus-host disease
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Myeloid-leukaemia in France (IV, Injection)
- 28 Jul 2021 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Injection)
- 13 Jun 2018 Phase I development in Solid tumours and Myeloid leukaemia is ongoing in USA and France respectively (Pharmagenesis pipeline, June 2018)